The largest psychiatric safety meta-analysis to date found that GLP-1 medications were not associated with increased risk of serious psychiatric adverse events overall ( Pierret et al., JAMA Psychiatry, 2025 ), and a post-hoc analysis of the major semaglutide weight management trials found no differences in depression, suicidal ideation, or suicidal behavior compared to placebo ( Wadden et al., JAMA Internal Medicine, 2024 )
The fluid path goes directly from barrel to needle with no expansion chamber to trap residual medication
Highlights from the ATTAIN-2 and ACHIEVE-3 trials demonstrate Orforglipron's significant therapeutic potential: Weight Reduction: In the ATTAIN-2 study (T2D & Obesity), the 36 mg dose achieved a -10.5% (-10.4 kg) body weight reduction at 52 weeks
Naynava, S
Evidence that trimethyllysine hydroxylase catalyzes the formation of (2 S ,3 S )-3-hydroxy- N -trimethyllysine
Lifehacks for Drinking Alcohol: Making alcohol less toxic